search
Back to results

A Clinical Trial of Safety and Tolerance of TQH3821 Tablets in Adult Healthy Subjects

Primary Purpose

Rheumatoid Arthritis

Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
TQH3821 tablets
TQH3821 tablets (Placebo)
Methotrexate tablets
Sponsored by
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Rheumatoid Arthritis

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • 1 Sign an informed consent form before the test, and fully understand the content, process and possible adverse reactions of the test;
  • 2 Be able to complete the research according to the requirements of the plan;
  • 3 Subjects (including partners) are willing to voluntarily take effective contraception within 6 months from screening to the last study drug administration;
  • 4 Male and female subjects aged 18 to 55 years (including critical value);
  • 5 Male subjects weigh not less than 50 kg, female subjects weigh not less than 45 kg, BMI in the range of 18 ~ 28 kg / m2 (including critical value);
  • 6 Physical examination, normal or abnormal vital signs are of no clinical significance

Exclusion Criteria:

  • 1 Those who smoke more than 5 cigarettes per day in the 12 weeks before screening;
  • 2 Allergic constitution (a variety of drug and food allergies);
  • 3 Have a history of substance abuse, drug and/or alcohol abuse;
  • 4 Donate blood or lose a lot of blood (> 450 mL) within 12 weeks prior to screening;
  • 5 Take any drug that alters the activity of liver enzymes 28 days before screening, or combined with inhibitors or inducers of Cytochrome P4503A4 enzyme (CYP3A4 );
  • 6 Took any prescription drugs, over-the-counter drugs, any vitamin products or herbs within 14 days prior to screening;
  • 7 Those who have taken a special diet or have strenuous exercise within 2 weeks before screening, or other factors that affect drug absorption, distribution, metabolism, excretion and other factors;
  • 8 Those who are vaccinated with live attenuated vaccines within 28 days before the start of research treatment, inactivated vaccines within 7 days, or vaccinated during the study period;
  • 9 Have taken research drugs within 12 weeks before taking our research drugs, or participated in clinical trials of drugs;
  • 10 Have a history of dysphagia or any gastrointestinal diseases that affect the absorption of the drug or a history of gallbladder resection or biliary tract diseases;
  • 11 Have any disease that increases the risk of bleeding, such as hemorrhoids, acute gastritis or stomach and duodenal ulcers;
  • 12 Subjects who could not tolerate a standard meal; (only applies to subjects participating in the postprandial test);
  • 13 Electrocardiogram (ECG) abnormalities have clinical significance;
  • 14 Female subjects are breastfeeding during the screening period or during the test or have a positive serum pregnancy result;
  • 15 Diseases with abnormal clinical significance in clinical laboratory examination or other clinical findings within 24 weeks before screening;
  • 16 Positive screening for viral hepatitis (including hepatitis B and C), Acquired Immune Deficiency Syndrome (AIDS) antibodies, treponemal antibodies;
  • 17 Acute illness or concomitant medication from the screening stage to the study of medication;
  • 18 Chocolate, any caffeinated or xanthine-rich foods or beverages taken 24 hours before taking the study drug;
  • 19 Have taken any products containing alcohol within 24 hours before taking the research medication;
  • 20 Positive for urine drug screening;
  • 21 Participants who were considered by the investigators to have other factors that were not suitable for this trial.

Sites / Locations

  • The Affiliated Hospital of Qingdao UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm Type

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Experimental

Placebo Comparator

Arm Label

TQH3821 Tablets (Single Administration Dose)

TQH3821 Tablets (Placebo) (Single Administration Dose)

TQH3821 Tablets (Food Effect)

TQH3821 Tablets (Placebo) (Food Effect)

TQH3821 Tablets (Multiple Administration Dose)

TQH3821 Tablets (Placebo) (Multiple Administration Dose)

TQH3821 Tablets + Methotrexate Tablets

TQH3821 Tablets (Placebo) + Methotrexate Tablets

Arm Description

TQH3821 tablets,Single administration

TQH3821 Tablets (Placebo), Single administration

TQH3821 tablets, 2 sequential periods (fasting and fed)

TQH3821 Tablets (Placebo), 2 sequential periods (fasting and fed)

Take TQH3821 tablets 11 times

Take TQH3821 Tablets (Placebo) 11 times

Take TQH3821 Tablets once in the first cycle, take Methotrexate Tablets once in the second cycle, and take TQH3821 Tablets + Methotrexate Tablets in the third cycle

Take TQH3821 Tablets (Placebo) once in the first cycle, take Methotrexate Tablets once in the second cycle, and take TQH3821 Tablets (Placebo) + Methotrexate Tablets in the third cycle

Outcomes

Primary Outcome Measures

Safety and tolerability
Safety and tolerability are assessed by observing adverse reactions or serious conditions caused by the drug during or after use.

Secondary Outcome Measures

Peak concentration (Cmax)
Peak concentration (Cmax) refers to the highest blood drug concentration achieved after administration called blood drug peak concentration (referred to as peak concentration), which is related to the dose administered, the route of administration, the number of times of administration and the time of arrival
Plasma concentration-area under time curve (AUC0-t)
The area under the plasma concentration-time curve from the beginning of the first administration to the last measurable concentration point
Plasma concentration-area under time curve (AUC0-∞)
Extrapolated from the first administration to the area under the plasma concentration-time curve to infinity
High sensitivity C-reactive protein (hs-CRP)
Hypersensitive C-reactive protein is a kind of C-reactive protein in plasma. It is a non-specific marker of acute systemic inflammatory response synthesized by the liver

Full Information

First Posted
May 16, 2022
Last Updated
May 16, 2022
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05380934
Brief Title
A Clinical Trial of Safety and Tolerance of TQH3821 Tablets in Adult Healthy Subjects
Official Title
A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial of TQH3821 in Adult Healthy Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
May 2022
Overall Recruitment Status
Recruiting
Study Start Date
May 2022 (Anticipated)
Primary Completion Date
April 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This study was a randomized, double-blind, placebo-controlled phase I clinical trial of TQH3821 in adult healthy subjects, which plans to recruit 62 healthy subjects. The main purpose was to evaluate the safety and tolerance of TQH3821 in multiple doses, single and multiple times in healthy subjects and in combination with methotrexate tablets.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rheumatoid Arthritis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
62 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
TQH3821 Tablets (Single Administration Dose)
Arm Type
Experimental
Arm Description
TQH3821 tablets,Single administration
Arm Title
TQH3821 Tablets (Placebo) (Single Administration Dose)
Arm Type
Placebo Comparator
Arm Description
TQH3821 Tablets (Placebo), Single administration
Arm Title
TQH3821 Tablets (Food Effect)
Arm Type
Experimental
Arm Description
TQH3821 tablets, 2 sequential periods (fasting and fed)
Arm Title
TQH3821 Tablets (Placebo) (Food Effect)
Arm Type
Placebo Comparator
Arm Description
TQH3821 Tablets (Placebo), 2 sequential periods (fasting and fed)
Arm Title
TQH3821 Tablets (Multiple Administration Dose)
Arm Type
Experimental
Arm Description
Take TQH3821 tablets 11 times
Arm Title
TQH3821 Tablets (Placebo) (Multiple Administration Dose)
Arm Type
Placebo Comparator
Arm Description
Take TQH3821 Tablets (Placebo) 11 times
Arm Title
TQH3821 Tablets + Methotrexate Tablets
Arm Type
Experimental
Arm Description
Take TQH3821 Tablets once in the first cycle, take Methotrexate Tablets once in the second cycle, and take TQH3821 Tablets + Methotrexate Tablets in the third cycle
Arm Title
TQH3821 Tablets (Placebo) + Methotrexate Tablets
Arm Type
Placebo Comparator
Arm Description
Take TQH3821 Tablets (Placebo) once in the first cycle, take Methotrexate Tablets once in the second cycle, and take TQH3821 Tablets (Placebo) + Methotrexate Tablets in the third cycle
Intervention Type
Drug
Intervention Name(s)
TQH3821 tablets
Intervention Description
TQH3821 tablets is an Interleukin-1 receptor-associated kinase 4 inhibitor that exhibits a high degree of inhibitory activity against IRAK4 kinase.
Intervention Type
Drug
Intervention Name(s)
TQH3821 tablets (Placebo)
Intervention Description
TQH3821 tablets (Placebo) is a placebo produced with reference to TQH3821 tablets, which has no effect on IRAK4 kinase.
Intervention Type
Drug
Intervention Name(s)
Methotrexate tablets
Intervention Description
Methotrexate tablets is a folic acid antagonist, which belongs to an anti-rheumatic drug to improve the condition
Primary Outcome Measure Information:
Title
Safety and tolerability
Description
Safety and tolerability are assessed by observing adverse reactions or serious conditions caused by the drug during or after use.
Time Frame
The first day of the first administration until 8 days after the last administration
Secondary Outcome Measure Information:
Title
Peak concentration (Cmax)
Description
Peak concentration (Cmax) refers to the highest blood drug concentration achieved after administration called blood drug peak concentration (referred to as peak concentration), which is related to the dose administered, the route of administration, the number of times of administration and the time of arrival
Time Frame
Pharmacokinetics blood samples were collected from 60 minutes before administration on Day 1 to 168 hours after the last administration.
Title
Plasma concentration-area under time curve (AUC0-t)
Description
The area under the plasma concentration-time curve from the beginning of the first administration to the last measurable concentration point
Time Frame
Pharmacokinetics blood samples were collected from 60 minutes before administration on Day 1 to 168 hours after the last administration.
Title
Plasma concentration-area under time curve (AUC0-∞)
Description
Extrapolated from the first administration to the area under the plasma concentration-time curve to infinity
Time Frame
Pharmacokinetics blood samples were collected from 60 minutes before administration on Day 1 to 168 hours after the last administration.
Title
High sensitivity C-reactive protein (hs-CRP)
Description
Hypersensitive C-reactive protein is a kind of C-reactive protein in plasma. It is a non-specific marker of acute systemic inflammatory response synthesized by the liver
Time Frame
Multiple Administration Dose: Blood samples were collected from 60 minutes before administration on Day 1 to 216 hours after administration on Day 9.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: 1 Sign an informed consent form before the test, and fully understand the content, process and possible adverse reactions of the test; 2 Be able to complete the research according to the requirements of the plan; 3 Subjects (including partners) are willing to voluntarily take effective contraception within 6 months from screening to the last study drug administration; 4 Male and female subjects aged 18 to 55 years (including critical value); 5 Male subjects weigh not less than 50 kg, female subjects weigh not less than 45 kg, BMI in the range of 18 ~ 28 kg / m2 (including critical value); 6 Physical examination, normal or abnormal vital signs are of no clinical significance Exclusion Criteria: 1 Those who smoke more than 5 cigarettes per day in the 12 weeks before screening; 2 Allergic constitution (a variety of drug and food allergies); 3 Have a history of substance abuse, drug and/or alcohol abuse; 4 Donate blood or lose a lot of blood (> 450 mL) within 12 weeks prior to screening; 5 Take any drug that alters the activity of liver enzymes 28 days before screening, or combined with inhibitors or inducers of Cytochrome P4503A4 enzyme (CYP3A4 ); 6 Took any prescription drugs, over-the-counter drugs, any vitamin products or herbs within 14 days prior to screening; 7 Those who have taken a special diet or have strenuous exercise within 2 weeks before screening, or other factors that affect drug absorption, distribution, metabolism, excretion and other factors; 8 Those who are vaccinated with live attenuated vaccines within 28 days before the start of research treatment, inactivated vaccines within 7 days, or vaccinated during the study period; 9 Have taken research drugs within 12 weeks before taking our research drugs, or participated in clinical trials of drugs; 10 Have a history of dysphagia or any gastrointestinal diseases that affect the absorption of the drug or a history of gallbladder resection or biliary tract diseases; 11 Have any disease that increases the risk of bleeding, such as hemorrhoids, acute gastritis or stomach and duodenal ulcers; 12 Subjects who could not tolerate a standard meal; (only applies to subjects participating in the postprandial test); 13 Electrocardiogram (ECG) abnormalities have clinical significance; 14 Female subjects are breastfeeding during the screening period or during the test or have a positive serum pregnancy result; 15 Diseases with abnormal clinical significance in clinical laboratory examination or other clinical findings within 24 weeks before screening; 16 Positive screening for viral hepatitis (including hepatitis B and C), Acquired Immune Deficiency Syndrome (AIDS) antibodies, treponemal antibodies; 17 Acute illness or concomitant medication from the screening stage to the study of medication; 18 Chocolate, any caffeinated or xanthine-rich foods or beverages taken 24 hours before taking the study drug; 19 Have taken any products containing alcohol within 24 hours before taking the research medication; 20 Positive for urine drug screening; 21 Participants who were considered by the investigators to have other factors that were not suitable for this trial.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yu Cao, Doctor
Phone
0532-82917310
Email
caoyu1767@126.com
Facility Information:
Facility Name
The Affiliated Hospital of Qingdao University
City
Qingdao
State/Province
Shandong
ZIP/Postal Code
266003
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yu Cao
Phone
053282917310
Email
caoyu1767@126.com

12. IPD Sharing Statement

Learn more about this trial

A Clinical Trial of Safety and Tolerance of TQH3821 Tablets in Adult Healthy Subjects

We'll reach out to this number within 24 hrs